Clinical Trial Update: Rituximab Maintenance After Autologous Transplantation [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating rituximab maintenance after autologous transplantation in non-Hodgkin lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Non-Hodgkin's Lymphoma | Phase 3 | Status: TERMINATED